Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
OBJECTIVES:
* Determine the frequency of epidermal growth factor receptor (EGFR) and K-ras mutations in patients with stage III non-small cell lung cancer (NSCLC) treated on CALGB 30106.
* Correlate presence or absence of EGFR and/or K-ras mutations with radiographic response to treatment in these patients.
OUTLINE: Tissue samples are analyzed for epidermal growth factor receptor and K-ras mutations.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Eligible patients had histologic documentation of un- treated stage III NSCLC.
2. Radiation oncologist confirmation was required that radiation could be given per protocol.
3. Eastern Cooperative Group Criteria Performance Status of 0 to 2
4. Tumor specimen paraffin block or unstained slides and standard initial laboratory tests
5. Signed institutional review board-approved, protocol-specific in- formed consent in accordance with federal and institutional guidelines
You may not be if
1\. Patients with scalene, supraclavicular, or contralateral hilar lymph node involvement, or direct invasion of the vertebral body or with a pleural effusion were ineligible.